Lloyd J Old

Summary

Affiliation: Ludwig Institute for Cancer Research
Country: Belgium

Publications

  1. ncbi request reprint Cancer Vaccine Collaborative 2002: opening address
    Lloyd J Old
    Ludwig Institute for Cancer Research, New York Branch of Human Cancer Immunology at Memorial Sloan Kettering Cancer Center, New York 10158, USA
    Cancer Immun 3:1. 2003
  2. ncbi request reprint Cancer vaccines 2003: opening address
    Lloyd J Old
    Ludwig Institute for Cancer Research, New York Branch of Human Cancer Immunology at Memorial Sloan Kettering Cancer Center, New York 10158, USA
    Cancer Immun 3:1. 2003
  3. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
  4. pmc Rapid evolution of cancer/testis genes on the X chromosome
    Brian J Stevenson
    Ludwig Institute for Cancer Research and Swiss Institute of Bioinformatics, Lausanne, Switzerland
    BMC Genomics 8:129. 2007
  5. pmc A human monoclonal autoantibody to breast cancer identifies the PDZ domain containing protein GIPC1 as a novel breast cancer-associated antigen
    Sergei Rudchenko
    College of Physicians and Surgeons, Columbia University, 630 W, 168 St, New York, NY 10032, USA
    BMC Cancer 8:248. 2008
  6. ncbi request reprint Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients
    Djordje Atanackovic
    Ludwig Institute for Cancer Research, and Department of Human Immunogenetics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 172:3289-96. 2004
  7. pmc PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses
    Wilson A Silva
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 7:18. 2007
  8. doi request reprint Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination
    Takemasa Tsuji
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Immunol 183:4800-8. 2009
  9. pmc Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 100:8862-7. 2003
  10. ncbi request reprint NY-ESO-1: review of an immunogenic tumor antigen
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Adv Cancer Res 95:1-30. 2006

Detail Information

Publications89

  1. ncbi request reprint Cancer Vaccine Collaborative 2002: opening address
    Lloyd J Old
    Ludwig Institute for Cancer Research, New York Branch of Human Cancer Immunology at Memorial Sloan Kettering Cancer Center, New York 10158, USA
    Cancer Immun 3:1. 2003
  2. ncbi request reprint Cancer vaccines 2003: opening address
    Lloyd J Old
    Ludwig Institute for Cancer Research, New York Branch of Human Cancer Immunology at Memorial Sloan Kettering Cancer Center, New York 10158, USA
    Cancer Immun 3:1. 2003
  3. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  4. pmc Rapid evolution of cancer/testis genes on the X chromosome
    Brian J Stevenson
    Ludwig Institute for Cancer Research and Swiss Institute of Bioinformatics, Lausanne, Switzerland
    BMC Genomics 8:129. 2007
    ..While it has been shown that some CT genes are under diversifying selection, this question has not been addressed before for the class as a whole...
  5. pmc A human monoclonal autoantibody to breast cancer identifies the PDZ domain containing protein GIPC1 as a novel breast cancer-associated antigen
    Sergei Rudchenko
    College of Physicians and Surgeons, Columbia University, 630 W, 168 St, New York, NY 10032, USA
    BMC Cancer 8:248. 2008
    ....
  6. ncbi request reprint Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients
    Djordje Atanackovic
    Ludwig Institute for Cancer Research, and Department of Human Immunogenetics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 172:3289-96. 2004
    ..This development provides the framework for further evaluating integrated immune responses in vaccine settings and for optimizing these responses for clinical benefit...
  7. pmc PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses
    Wilson A Silva
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 7:18. 2007
    ..We found by ELISA that PLAC1 is immunogenic in a subset of cancer patients and healthy women. Its physical and expression characteristics render it a potential target for both active and passive cancer immunotherapeutic strategies...
  8. doi request reprint Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination
    Takemasa Tsuji
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Immunol 183:4800-8. 2009
    ..It appeared that MAGE-A3 protein vaccination in the presence of adjuvant selectively expanded high avidity CD4+ T cells, whereas high avidity T cells disappeared after multiple vaccinations with MAGE-A3 protein alone...
  9. pmc Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 100:8862-7. 2003
    ....
  10. ncbi request reprint NY-ESO-1: review of an immunogenic tumor antigen
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Adv Cancer Res 95:1-30. 2006
    ..An overview of immunological findings and immunotherapeutic approaches with NY-ESO-1, as well the role of regulation in NY-ESO-1 immunogenicity, is presented here...
  11. pmc Immunomic analysis of human sarcoma
    Sang Yull Lee
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 100:2651-6. 2003
    ..NY-SAR-35 is therefore a potential target for cancer vaccines and monoclonal antibody-based immunotherapies...
  12. pmc In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines
    Hiroyoshi Nishikawa
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York 10021, and Section of Microbial Pathogenesis, Yale University School of Medicine, New Haven, Connecticut 06536, USA
    J Clin Invest 116:1946-54. 2006
    ..We propose that antigen delivery through the S. typhimurium type III secretion system is a promising novel strategy for cancer vaccine development...
  13. ncbi request reprint Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC
    Djordje Atanackovic
    Ludwig Institute for Cancer Research, Branch at Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 32, New York, NY 10021, USA
    J Immunol Methods 278:57-66. 2003
    ..This approach makes it possible to monitor CD4+ T cells in large series of patients, regardless of HLA haplotype, against the full peptide repertoire of a given antigen...
  14. ncbi request reprint Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 170:1191-6. 2003
    ..e., HLA eligibility criteria and knowledge of epitope, while allowing for facilitated immunogenicity in the presence of helper epitopes...
  15. ncbi request reprint Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer
    Ali O Gure
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:8055-62. 2005
    ..We asked whether cancer-testis gene expression occurred coordinately, and whether it correlated with variables of disease and clinical outcome of non-small cell lung cancer (NSCLC)...
  16. pmc IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation
    Mitsutoshi Matsuo
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 101:14467-72. 2004
    ..This model of conditional cross-presentation establishes an original level of action for IFN-gamma as an effective immune modulator and supports the use of IFN-gamma in protein vaccination strategies targeting LCs...
  17. doi request reprint Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells
    Takemasa Tsuji
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Immunol 188:3851-8. 2012
    ..Furthermore, targeted activation of tumor-recognizing CD4(+) T cells by vaccination or adoptive transfer could be a suitable strategy for enhancing the efficacy of tumor immunotherapy...
  18. pmc Expression of cancer-testis (CT) antigens in placenta
    Achim A Jungbluth
    New York Branch, Ludwig Institute for Cancer Research, New York, NY 10021, USA
    Cancer Immun 7:15. 2007
    ..However, our data indicate that the various CT antigens have different functions during placental development...
  19. ncbi request reprint Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination
    Hiroyoshi Nishikawa
    Ludwig Institute for Cancer Research, New York Branch, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Immunol 176:6340-6. 2006
    ..We propose that vaccination with NY-ESO-1(157-170) peptide recruits low-avidity T cells with low sensitivity to Tregs and fails to modulate the suppressive effect of Tregs on high-avidity NY-ESO-1-specific T cell precursors...
  20. ncbi request reprint Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector
    Hiroyoshi Nishikawa
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 111:1404-12. 2008
    ..We propose that S typhimurium-NY-ESO-1 induces antigen-specific T-cell responses that are resistant to suppression by CD4(+)CD25(+) Treg cells...
  21. ncbi request reprint Identification of the gonad-specific anion transporter SLCO6A1 as a cancer/testis (CT) antigen expressed in human lung cancer
    Sang Yull Lee
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Immun 4:13. 2004
    ..The analysis also permits us to estimate the eventual size of the SEREX-defined cancer immunome at around 4000 genes. This emphasizes the importance of continued SEREX screening to define the cancer immunome...
  22. ncbi request reprint Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
    Matthew J Scanlan
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, Department of Pathology, New York, NY 10021, USA
    Immunol Rev 188:22-32. 2002
    ..Since CT antigens are immunogenic and highly restricted to tumors, their discovery has led directly to the development of antigen-specific cancer vaccines, and clinical trials with MAGE-A and NY-ESO-1 are in progress...
  23. ncbi request reprint Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer
    Padmanee Sharma
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 3:19. 2003
    ..This patient's T-cell response was determined to be specific for a new NY-ESO-1 epitope, p94-102, in the context of HLA-B35...
  24. pmc CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 99:11813-8. 2002
    ....
  25. doi request reprint NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, New York Branch, Memorial Sloan Kettering Cancer Center, New York, USA
    Clin Cancer Res 15:2130-9. 2009
    ..Here, we report for the first time clinical and immune responses generated by the NY-ESO-1 DNA vaccine administered by particle-mediated epidermal delivery to cancer patients...
  26. ncbi request reprint Glycoprotein A34, a novel target for antibody-based cancer immunotherapy
    Matthew J Scanlan
    Ludwig Institute for Cancer Research, New York Branch of Human Cancer Immunology at Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Immun 6:2. 2006
    ..The A34 antigen and monoclonal antibody may be of considerable value for immunotherapy of different types of cancer...
  27. ncbi request reprint CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients
    Hiroyoshi Nishikawa
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 32 Rm K 817, New York, NY 10021, USA
    Blood 106:1008-11. 2005
    ..Memory populations were less sensitive than naive populations to CD4+CD25+ regulatory T cells. We propose that CD4+CD25+ regulatory T cells are involved in the generation and regulation of NY-ESO-1-specific antitumor immunity...
  28. ncbi request reprint NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 127:381-93. 2010
    ..Importantly, NY-CO-58/KIF2C was able to induce spontaneous CD4(+) T cell responses of the Th1-type, which were tightly controlled by peripheral T regulatory cells...
  29. ncbi request reprint Cancer/testis antigens, gametogenesis and cancer
    Andrew J G Simpson
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Nat Rev Cancer 5:615-25. 2005
    ....
  30. ncbi request reprint Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets
    Matthew J Scanlan
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 62:4041-7. 2002
    ..In contrast, 9 of 9 colon cancer specimens showed overexpression of KNSL6 mRNA, ranging from 5 to 44 times the level detected in normal colon tissue, indicating that this antigen could also be a valuable therapeutic target...
  31. pmc A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor
    Achim A Jungbluth
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 100:639-44. 2003
    ..Our study also indicates that DeltaEGFR is restricted to glioblastoma, in contrast to other reports that this mutation is found in tumors outside the brain...
  32. ncbi request reprint The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation
    Achim A Jungbluth
    New York Branch, Ludwig Institute for Cancer Research, New York, NY, USA
    Blood 106:167-74. 2005
    ..Furthermore, the common expression and correlation with proliferation suggest a possible pathogenic role for these proteins in myeloma...
  33. pmc Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas
    Beatrice W T Yin
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Immun 8:3. 2008
    ..Membrane transporter molecules, such as NaPi2b, represent a new family of potential cell surface targets for the immunotherapy of cancer with monoclonal antibodies...
  34. ncbi request reprint CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues
    Achim A Jungbluth
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 99:839-45. 2002
    ....
  35. ncbi request reprint The SSX gene family: characterization of 9 complete genes
    Ali O Gure
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 101:448-53. 2002
    ..These agents also induce SSX6, but not SSX3, 7, 8 or 9 in the tumor cell lines tested, indicating that mechanisms other than methylation or histone acetylation may be responsible for the repressed state of some SSX genes...
  36. pmc Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
    Eiichi Sato
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 102:18538-43. 2005
    ..We conclude that intraepithelial CD8+ TILs and a high CD8+/Treg ratio are associated with favorable prognosis in epithelial ovarian cancer...
  37. ncbi request reprint Cancer vaccines: an overview
    Lloyd J Old
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer Immun 8:1. 2008
    ....
  38. doi request reprint Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity
    Takemasa Tsuji
    Ludwig Institute for Cancer Research, Ltd, New York Branch, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Immunol 186:1218-27. 2011
    ..Receptor-specific delivery of NY-ESO-1 to APC appears to be a promising vaccination strategy to efficiently generate integrated and broad Ag-specific immune responses against NY-ESO-1 in cancer patients...
  39. pmc CT-X antigen expression in human breast cancer
    Anita Grigoriadis
    Ludwig Institute for Cancer Research, 605 Third Avenue, New York, NY 10158, USA
    Proc Natl Acad Sci U S A 106:13493-8. 2009
    ..Because of the limited therapeutic options for ER-negative breast cancers, vaccines based on CT-X antigens might prove to be useful...
  40. ncbi request reprint The cancer/testis genes: review, standardization, and commentary
    Matthew J Scanlan
    Ludwig Institute for Cancer Research, New York Branch of Human Cancer Immunology at Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Immun 4:1. 2004
    ....
  41. doi request reprint Autoantibodies against cancer antigens
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Methods Mol Biol 520:11-9. 2009
    ..We describe in this chapter a simple implementation of a serological monitoring platform for autoantibody measurement in cancer patients, from production of recombinant antigens to ELISA testing and interpretation...
  42. ncbi request reprint Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51
    Elke Jager
    II Medizinische Klinik, Hämatologie Onkologie, Krankenhaus Nordwest, Frankfurt, Germany
    Cancer Immun 2:12. 2002
    ....
  43. pmc Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients
    Elke Jager
    Ludwig Institute Clinical Trial Center, Medizinische Klinik II, Hämatologie Onkologie, Krankenhaus Nordwest, Steinbacher Hohl 2 26, 60488 Frankfurt, Germany
    Proc Natl Acad Sci U S A 103:14453-8. 2006
    ..In several patients with melanoma, there was a strong impression that the natural course of the disease was favorably influenced by vaccination...
  44. ncbi request reprint Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum
    Dirk Jager
    II Medizinische Klinik, Hämatologie Onkologie, Krankenhaus Nordwest, Frankfurt, Germany
    Cancer Immun 2:5. 2002
    ..This study provides further evidence that SEREX is a powerful tool to identify new tumor antigens potentially relevant for immunotherapy approaches...
  45. pmc Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations
    Yasuhiro Nagata
    Ludwig Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 99:10629-34. 2002
    ..These results indicate that monocyte-derived DCs will be easier to load by using protein antigen in vitro than CD34-derived DCs, and that the latter population exhibits a restricted ability to crosspresent soluble exogenous antigens...
  46. ncbi request reprint Identification of cancer/testis genes by database mining and mRNA expression analysis
    Matthew J Scanlan
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 98:485-92. 2002
    ..This study demonstrates the merits of database mining with respect to the identification of tissue-restricted gene products expressed in cancer...
  47. ncbi request reprint Identification and characterization of mouse SSX genes: a multigene family on the X chromosome with restricted cancer/testis expression
    Yao Tseng Chen
    Weill Medical College of Cornell University, 10021, New York, NY, USA
    Genomics 82:628-36. 2003
    ..All putative human and mouse SSX proteins share conserved KRAB and SSX-RD domains. Mouse tumors were found to express some, but not all, Ssxb genes, similar to the SSX activation in human tumors...
  48. pmc Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer
    Kunle Odunsi
    Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Proc Natl Acad Sci U S A 104:12837-42. 2007
    ....
  49. ncbi request reprint Expression and purification of the cancer antigen SSX2: a potential cancer vaccine
    Chung Jr Huang
    Graduate Field of Microbiology, Cornell University, Ithaca, NY 14853, USA
    Protein Expr Purif 56:212-9. 2007
    ..11EU/microg. The purified recombinant SSX2 was characterized by ELISA and was shown to be recognized by human sera that have been reported to carry anti-SSX2 antibodies...
  50. pmc LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer
    Armin Bender
    Klinik für Onkologie und Hämatologie, Krankenhaus Nordwest, Frankfurt, Germany
    Cancer Immun 7:16. 2007
    ..A specific immune response of high magnitude and early onset may be more effective in eliminating minimal residual disease in adjuvant treatment situations and in preventing tumor progression due to immune escape mechanisms...
  51. ncbi request reprint Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen
    Monica Rodolfo
    Units of Melanoma Genetics, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy
    Cancer Res 63:6948-55. 2003
    ..We conclude that NY-ESO-1 is an immunogenic antigen in neuroblastoma patients and represents a candidate target for immune-based therapy...
  52. ncbi request reprint NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer
    Kunle Odunsi
    Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer Res 63:6076-83. 2003
    ..These findings indicate that NY-ESO-1 and LAGE-1 are attractive targets for antigen-specific immunotherapy in EOC...
  53. ncbi request reprint Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma
    Susann Szmania
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    J Immunother 30:847-54. 2007
    ..MAGE-A3 immunization may be a useful adjunct to high dose melphalan-based peripheral blood stem cell transplant, providing a new therapeutic option for high-risk MM...
  54. pmc Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming
    Djordje Atanackovic
    Department of Oncology Hematology, University Medical Center Hamburg Eppendorf, 20246 Hamburg, Germany
    Proc Natl Acad Sci U S A 105:1650-5. 2008
    ..These data provide an immunological rationale for vaccine design in light of recently reported favorable clinical responses in NSCLC patients after vaccination with MAGE-A3 protein plus adjuvant AS02B...
  55. ncbi request reprint Expression of cancer/testis (CT) antigens in lung cancer
    Kouhei Tajima
    Division of Immunology, Aichi Cancer Center Research Institute, 1 1, Kanokoden, Chikusa ku, Nagoya, Aichi 464 8681, Japan
    Lung Cancer 42:23-33. 2003
    ..In addition, in silico surveys of dbEST database were used for identification of new CT antigens. We identified a novel gene, TES101RP, expressed only in some small cell lung cancers (SCLC) and in testis, as confirmed by RT-PCR analysis...
  56. ncbi request reprint A new member of the NY-ESO-1 gene family is ubiquitously expressed in somatic tissues and evolutionarily conserved
    Birgit Alpen
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Gene 297:141-9. 2002
    ..In addition, an intronless and presumably non-coding, copy of the mESO3, psimESO3, was identified on mouse chromosome 15. No counterpart of the ESO1 or 2 genes was found in rodents...
  57. pmc Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting
    Valerie Dutoit
    Ludwig Institute Clinical Trial Center, New York Branch at Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    J Clin Invest 110:1813-22. 2002
    ....
  58. ncbi request reprint Urine antibody against human cancer antigen NY-ESO-1
    Dirk Jager
    II Medizinische Klinik, Hämatologie Onkologie, Krankenhaus Nordwest, Frankfurt, Germany
    Cancer Immun 2:10. 2002
    ..Urine antibody detection may also be of value in the monitoring of spontaneous and vaccine-induced immunity against other defined tumor antigens...
  59. doi request reprint Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient
    Kazuhide Tsuji
    Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    Cancer Immunol Immunother 57:1429-37. 2008
    ..Cholesterol-bearing hydrophobized pullulan (CHP) is a nanoparticle-forming antigen-delivery vehicle and CHP complexed with NY-ESO-1 protein (CHP-NY-ESO-1) efficiently activates CD4 and CD8 T cells in vitro...
  60. ncbi request reprint NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer
    Tetsuya Nakada
    Department of Immunology, Okayama University Graduate School of Medicine and Dentistry, Japan
    Cancer Immun 3:10. 2003
    ..CD8 T cell responses specific to NY-ESO-1 were detected in two of three patients with NY-ESO-1 antibodies...
  61. doi request reprint Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission
    Catherine S M Diefenbach
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:2740-8. 2008
    ..In this study, we describe the effects of vaccination with the HLA-A*0201-restricted NY-ESO-1b peptide on patients with epithelial ovarian cancer in high-risk first remission...
  62. pmc Cancer-testis (CT) antigen expression in medulloblastoma
    Sueli M Oba-Shinjo
    Department of Neurology, School of Medicine, University of Sao Paulo, Av Dr Arnaldo, 455, Room 4110, Sao Paulo, Brazil
    Cancer Immun 8:7. 2008
    ....
  63. ncbi request reprint Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination
    Julia Karbach
    II Medizinische Klinik, Hämatologie Onkologie, Krankenhaus Nordwest, Frankfurt, Germany
    Int J Cancer 121:2042-8. 2007
    ....
  64. ncbi request reprint NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors
    Yurika Sugita
    Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, 2 2 Yamadaoka, Suita City, Osaka 565 0871, Japan
    Cancer Res 64:2199-204. 2004
    ....
  65. pmc Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming
    Danila Valmori
    Ludwig Institute Clinical Trial Center, Columbia University, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 104:8947-52. 2007
    ....
  66. pmc T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein
    Akiko Uenaka
    Department of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Shikata cho, Okayama, Japan
    Cancer Immun 7:9. 2007
    ..The use of whole protein, containing multiple CD4 and CD8 epitopes, may be beneficial for cancer vaccines to prevent tumors from evading the immune response...
  67. ncbi request reprint A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients
    Maha Ayyoub
    Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Clin Immunol 118:188-94. 2006
    ..We anticipate that this phenotype-based approach will be useful for the immune monitoring of vaccine-induced responses in vaccination trials using NY-ESO-1 as well as other tumor antigens...
  68. pmc Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans
    Ian D Davis
    Ludwig Institute for Cancer Research, Melbourne 3084, Australia
    Proc Natl Acad Sci U S A 101:10697-702. 2004
    ..In an unplanned analysis, vaccinated patients appeared to have superior clinical outcomes to those treated with placebo or protein alone. The vaccine is safe and highly potent immunologically...
  69. ncbi request reprint Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes
    Dirk Jager
    Medizinische Onkologie, Nationales Centrum fur Tumorerkrankungen, Universitätsklinik Heidelberg, Im Neuenheimer Feld 350, D 69120 Heidelberg, Germany
    Cancer Immun 5:11. 2005
    ..The identification of these two naturally processed NY-BR-1-specific CD8+ T cell epitopes opens the perspective for active immunotherapy of HLA-A2 positive patients with NY-BR-1 expressing tumors...
  70. ncbi request reprint The humoral immune response to head and neck cancer antigens as defined by the serological analysis of tumor antigens by recombinant cDNA expression cloning
    Hilary A Vaughan
    Cancer Vaccine Laboratory, Ludwig Institute for Cancer Research, Austin Health, Studley Road, Heidelberg, 3084, Australia
    Cancer Immun 4:5. 2004
    ..Whether AU-HN-15 represents a tumor-antigen target suitable for prognostic or therapeutic purposes is still being analyzed...
  71. ncbi request reprint Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011
    Julia Karbach
    II Medizinische Klinik, Hämatologie Onkologie, Krankenhaus Nordwest, Frankfurt, Germany
    Int J Cancer 118:668-74. 2006
    ..The characterization of the new HLA-DQ B1 03011-restricted NY-ESO-1 peptides broadens the repertoire of epitopes that can be used to monitor NY-ESO-1-specific spontaneous and vaccine-induced T-cell responses in cancer patients...
  72. ncbi request reprint Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments
    Gerhard Held
    Clinic for Internal Medicine I, Saarland University Medical School, Homburg Saar, Germany
    Eur J Immunol 34:2919-29. 2004
    ..It may therefore become a useful monitoring tool for the development of NY-ESO-1-based cancer vaccines...
  73. ncbi request reprint Serological identification of breast cancer-related antigens from a Saccharomyces cerevisiae surface display library
    Andreas Wadle
    I Med Klinik, Saarland University Medical School, Homburg Saar, Germany
    Int J Cancer 117:104-13. 2005
    ..The small breast epithelial mucin is present to a large extent in a membrane bound format and might be used for tumor targeting strategies...
  74. ncbi request reprint NY-ESO-1 expression and immunogenicity in esophageal cancer
    Shoichiro Fujita
    Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan
    Clin Cancer Res 10:6551-8. 2004
    ..We report here the frequency of NY-ESO-1 mRNA and protein expression in esophageal cancer and the presence of NY-ESO-1-specific immune response in patients...
  75. ncbi request reprint The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients
    Xiao Ying Shang
    Department of Immunology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, People s Republic of China
    Clin Cancer Res 10:6946-55. 2004
    ....
  76. ncbi request reprint Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1
    Hilary A Vaughan
    Ludwig Institute for Cancer Research, Melbourne, Australia
    Clin Cancer Res 10:8396-404. 2004
    ..This study evaluates typing strategies used to distinguish these two homologous but distinct antigens and to characterize and quantitate expression of each in clinical samples...
  77. ncbi request reprint Identification of a new cancer/testis gene family, CT47, among expressed multicopy genes on the human X chromosome
    Yao Tseng Chen
    Weill Medical College of Cornell University, New York, New York 10021, USA
    Genes Chromosomes Cancer 45:392-400. 2006
    ..The only species other than human in which a gene homologous to CT47 has been detected is the chimpanzee, with the predicted protein showing approximately 80% identity in its carboxy terminal region...
  78. pmc Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant
    Qiyuan Chen
    Ludwig Institute for Cancer Research, Austin Health, 145 163 Studley Road, Heidelberg, Victoria 3084, Australia
    Proc Natl Acad Sci U S A 101:9363-8. 2004
    ..This T cell response was vaccinated in most patients who expressed HLA-DR2. This study has systematically surveyed patients vaccinated with full-length tumor antigen for a vaccinated CD4 helper T cell response...
  79. ncbi request reprint Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients
    Ryohei Kawabata
    Department of Surgery, Graduate School of Medicine, Osaka University, 2 2 Yamada oka, Suita, Osaka 565 0871, Japan
    Int J Cancer 120:2178-84. 2007
    ..The antigenic epitopes recognized by antibodies in the vaccinated patients were similar to those recognized in cancer patients with spontaneous humoral immunity against NY-ESO-1...
  80. ncbi request reprint Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6)
    Hearn J Cho
    Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Cancer Immun 6:12. 2006
    ..This is the first report of direct interaction between two CT antigens and may be pertinent in the light of the frequently coordinated expression of these proteins...
  81. ncbi request reprint Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen
    Danila Valmori
    Ludwig Institute Clinical Trial Center, Department of Medicine, Columbia University College of Physicians and Surgeons, 650 West 168th Street, Black Building Room 20 09, New York, NY 10032, USA
    Clin Immunol 122:163-72. 2007
    ..Our results support the concept that epitope clustering within defined protein regions identifies tumor antigen immunodominant regions and suggest a general strategy for their identification...
  82. ncbi request reprint Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients
    Ian D Davis
    Ludwig Institute for Cancer Research, Austin Health, Studley Road, Heidelberg, Victoria 3084, Australia
    J Immunother 29:499-511. 2006
    ..MAGE-A10-specific T cells with a skewed T-cell receptor repertoire were detected in 1 patient in blood ex vivo and from tumor biopsies. Vaccination with FLDCs pulsed with peptides is safe and primes immune responses to cancer antigens...
  83. pmc An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR
    Maha Ayyoub
    Ludwig Institute Clinical Trial Center, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    J Clin Invest 113:1225-33. 2004
    ....
  84. ncbi request reprint Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles
    Emmanuelle Godefroy
    Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, 650 West 168th Street, Black Building Room 20 09, New York, NY 10032, USA
    Clin Immunol 121:54-62. 2006
    ..Identification of these epitopes will be instrumental for the evaluation of the immune response to Melan-A in cancer patients...
  85. ncbi request reprint A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples
    Heather M Jackson
    Ludwig Institute for Cancer Research, Melbourne Branch, Austin Health, Heidelberg VIC 3084, Australia
    J Immunol Methods 291:51-62. 2004
    ....
  86. ncbi request reprint Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells
    Maha Ayyoub
    Ludwig Institute Clinical Trial Center and Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    J Immunol 172:7206-11. 2004
    ..In contrast, it was efficiently presented by autologous dendritic cells, supporting the concept that processing by professional APC is the main pathway through which the CD4(+) T cell immunoresponse to tumor Ags occurs in vivo...
  87. ncbi request reprint Generation of monoclonal antibodies to cancer/testis (CT) antigen CT10/MAGE-C2
    Ran Zhuang
    Department of Immunology, Fourth Military Medical University, Xi an 710032, PR China
    Cancer Immun 6:7. 2006
    ..In tumors, we analyzed a limited number of cases displaying the typical heterogeneous CT expression pattern. Interestingly, immunoreactivity was seen solely in the nucleus: No staining was seen in the cytoplasm of tumor cells...
  88. ncbi request reprint In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope
    Kosei Hasegawa
    Department of Immunology, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan
    Clin Cancer Res 12:1921-7. 2006
    ....
  89. ncbi request reprint HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones
    Eduardo Huarte
    II Medizinische Klinik, Hämatologie Onkologie, Krankenhaus Nordwest, Frankfurt, Germany
    Cancer Immun 4:15. 2004
    ..The Th1 phenotype and effector functions of the CD4+ T cell clones described here provide an important rationale for the activation of antigen-specific CD4+ T cells along with CD8+ T cells in cancer vaccination strategies...